NIKKEI 225
27,534.61 -151.79 (-0.55%) HANG SENG
19,354.64 +539.82 (+2.87%) CRUDE OIL
72.79 +0.78 (+1.08%) GOLD FUTURES
1,795.30 -2.70 (-0.15%) DOW
33,597.92 +1.58 (+0.00%) BTC-GBP
13,811.93 -221.36 (-1.58%)
Hofseth BioCare ASA (0Q6H.L)
| Previous close | 0.00 |
| Open | 8.04 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 8.04 - 8.04 |
| 52-week range | 8.04 - 8.04 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT
Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon processors to ensure increased access to salmon off-cut for our production process.- In July, HBC successfully placed a private placement of 35,490,000 new shares at a subscription price of NOK 4.00 per share and raised gross proceeds of NOK 141 million.- In August, Mr. Jon Olav Ødegård was appointed CEO by t
- Globe Newswire
Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed to further investigate the gastro-intestinal (GI)-protective properties of the bioactive peptides contained in salmon-derived ProGo®. The preclinical study found that the soluble protein hydrolysate (SPH) powder, produced by HBC’s unique enzymatic protein hydrolysis process, helps restore a healthy
- Globe Newswire
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the proposals in the notice. Please find the minutes from the general meeting attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: joo@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier a
